ArticleMolecular medicine reports2025
Identification and validation of epithelial‑mesenchymal transition‑related genes for diabetic nephropathy by WGCNA and machine learning.
Article in Molecular medicine reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic nephropathy (DN) is the main cause of end‑stage renal disease, with epithelial‑mesenchymal transition (EMT) serving a key role in its initiation and progression. Nevertheless, the precise mechanisms involved remain unidentified. The present study aimed to identify the involvement of EMT‑related genes in the advancement of DN. Using the Gene Expression Omnibus database and the dbEMT 2.0 database, EMT‑related differentially expressed genes (DEGs) associated with DN were identified. Key EMT‑related genes were subjected to weighted gene co‑expression network analysis, machine learning and protein‑protein interaction network analyses and validated against validation datasets from GEO database. Receiver operating characteristic analysis was used to assess the diagnostic performance of these hub genes. To delve into their cellular clustering in DN, single‑nucleus RNA sequencing was conducted using the Kidney Integrative Transcriptomics database. Additionally, the CIBERSORT algorithm was used to determine the proportion of immune cell infiltration in DN samples. Reverse transcription‑quantitative PCR (RT‑qPCR) was used to assess the mRNA expression of fibronectin 1 (FN1) in the kidney of mice and patients with DN. After silencing FN1, the expression changes of EMT markers (E‑cadherin and vimentin) were detected by RT‑qPCR. FN1 was upregulated in DN, demonstrating good diagnostic performance according to ROC analysis. FN1 was associated with infiltration of immune cells. RT‑qPCR confirmed the increased expression of FN1 in the kidney of mice with DN and in the renal biopsy samples of patients with DN. After silencing FN1, the expression of E‑cadherin was upregulated, while the expression of vimentin was downregulated, indicating that EMT was inhibited. The present study identified FN1 as a diagnostic marker for DN. FN1 may serve key roles in the initiation and progression of DN by participating in EMT and upregulating various types of immune cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.